Seelos Therapeuticsincis A Clinical Stage Biopharmaceutical Company Based In New Yorkfounded In 2016The Company Trades On The Nasdaq Capital Market Under The Ticker Symbolseel Led By Raj Mehraph D Seelos Is Dedicated To Developing Treatments For Significant Unmet Needs In Central Nervous Systemcnsdisorders And Rare Diseases Seelos Has A Robust Pipeline That Includes Late Stage Clinical Assets Targeting Conditions Such As Acute Suicidal Ideation And Behavior In Major Depressive Disorderamyotrophic Lateral Sclerosisand Spinocerebellar Ataxiathe Company Is Also Exploring Early Stage Programs For Huntington S Diseasealzheimer S Diseaseand Parkinson S Diseasenotable Product Candidates Include Sls 002An Intranasal Ketamine Product Developed In Partnership With Aptargroupand Sublingual Ketamine Wafers Acquired From Ix Biopharma Ltd Seelos Actively Engages In Partnerships To Enhance Its Product Developmentincluding Collaborations With Duke University For Gene Therapy Studiesthe Company S Focus On Innovative Treatments Positions It To Serve A Wide Range Of Patients And Healthcare Providers
